logo
Human teeth evolved to fit our diet

Human teeth evolved to fit our diet

Yahoo4 days ago
As humans, one of our biggest evolutionary advantages is our chompers. Our combination of molars, canines, and incisors help us to consume a diverse and omnivorous diet, unlike many other animals. This dramatically expands the available menu for energy sources, and thus increases nutritional options and the chance of survival. But according to a study published on July 31 in the journal Science, our early hominin ancestors' desire to bite off more than they could literally chew is the likely reason for our dental evolution.
The findings come from a team led by researchers at Dartmouth College, and offer the human fossil record's first known evidence of what's known as behavioral drive—the tendency for a species to develop routines that are helpful for their survival before their physiology evolves to meet these demands.
'We can definitively say that hominins were quite flexible when it came to behavior and this was their advantage,' anthropologist and study lead author Luke Fannin said in a statement.
Fannin explained that anthropologists often discuss hominin behavioral and morphological changes as if they evolved in tandem with one another. Instead, his team's analysis indicates that early human behavior was its own evolutionary force—one with large implications for our physical and dietary journey.
Fannin and colleagues reached their conclusions by examining multiple sets of fossilized teeth from various hominin and primate species, starting with one of our distant relatives from 3.9 to 2.9 million years ago called Australopithecus afarensis. Researchers were particularly interested in their levels of graminoids, the carbon and oxygen isotopes left behind from eating grasses and sedges. They also looked at fossil teeth from two extinct primate species who were contemporaries of A. afarensis—huge terrestrial monkeys that looked similar to baboons called theropiths, as well as smaller herbivorous monkeys known as colobines.
The team discovered that while A. afarensis, theropiths, and colobines all initially preferred a diet heavy in insects, fruits, and flowers, they started shifting to the tougher, graminoid-heavy sedges and grasses 3.4 to 4.8 million years ago. However, these changing palettes came at least 700,000 years before their teeth and digestive systems optimized for the vegetation.
Then, about 2.3 million years ago, hominin teeth began exhibiting significantly smaller amounts of oxygen and carbon isotopes. According to researchers, this implies that the era's human ancestor—Homo rudolfensis—lessened their grass intake for oxygen-depleted water. They offered three possible theories for this. In one scenario, H. rudolfensis simply drank far more water than other primates and African animals. Another hypothesis is that they adopted behavior similar to today's hippopotamuses, spending their days submerged in water and eating at night. The explanation most consistent with early-human behavior, however, is that the hominins started harvesting underground, carbohydrate-rich plant parts like tubers and bulbs.
The latter argument tracks with a species rapidly growing in physical size and numbers. Energy-rich plants were everywhere, they didn't fight back like prey, and were more nutritious. At this point in history, ancient humans were also beginning to form stone tools that made searching for underground plants even easier.
'We propose that this shift to underground foods was a signal moment in our evolution,' Fannin said. 'It created a glut of carbs that were perennial—our ancestors could access them at any time of year to feed themselves and other people.'
According to study senior author Nathaniel Dominy, one of anthropology's remaining 'burning questions' is 'What did hominins do differently that other primates didn't do?''This work shows that the ability to exploit grass tissues may be our secret sauce,' he said.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Axis Research & Technologies Celebrates 10 Years of Innovation and Sets Its Sights on Vision for Building the First AI-Powered Smart Surgical Center
Axis Research & Technologies Celebrates 10 Years of Innovation and Sets Its Sights on Vision for Building the First AI-Powered Smart Surgical Center

Yahoo

time20 minutes ago

  • Yahoo

Axis Research & Technologies Celebrates 10 Years of Innovation and Sets Its Sights on Vision for Building the First AI-Powered Smart Surgical Center

Future Surgical Center to Be Powered by OMNIMED SmartOR™ Technology, Anchored on a World-Class University Campus and Driven by Axis Research IRVINE, Calif., August 05, 2025--(BUSINESS WIRE)--Axis Research & Technologies, a national leader in bioskills training and medical research environments, proudly marks its 10-year anniversary with a decade of expansion, innovation, and trusted partnerships across the healthcare ecosystem. As it celebrates this milestone, the company unveils its bold next step: a strategic initiative to build the nation's first AI-powered smart surgical center in collaboration with a world-class university. This next-generation facility will unite cadaveric training, surgical simulation, real-time telemetry, and AI-driven insights to support clinical education, medical device innovation, and procedural performance at scale. "We've spent the last 10 years building a trusted network of innovation and excellence," said Nick Moran, Chief Executive Officer of Axis. "As we look to the next decade, our vision is to evolve from best-in-class bioskills labs to the development of intelligent, integrated surgical ecosystems that accelerate discovery and improve outcomes." A National Network Built for Innovation Founded in 2015, Axis operates a network of advanced bioskills labs in Irvine, CA; Columbia (Baltimore), MD; Nashville, TN; and Houston, TX. Each facility is designed to accommodate complex, hands-on surgical training, cadaveric research, device development, and live broadcast education—all supported by Axis's experienced logistics, tissue sourcing, and technical teams. The company's Houston lab, launched in 2025, is strategically located near the Texas Medical Center and continues the Axis tradition of pairing location intelligence with industry demand to better serve surgeons, educators, and medtech leaders. "We've scaled carefully and intentionally to meet the needs of our partners," said Moran. "And now, we're focused on shaping what comes next—where performance, insight, and education converge." OMNIMED and SmartOR™: Powering Data-Driven Surgical Environments Several years ago, Axis became an early adopter and integration partner of OMNIMED™, a medical technology company that had been developing SmartOR™—a first-of-its-kind AI surgical telemetry platform. SmartOR™ captures real-time data across classroom, simulation, and operating room environments, giving educators, researchers, and developers unprecedented insight into tools, workflows, and performance outcomes. OMNIMED's platform is now fully embedded within Axis facilities, enabling predictive modeling, skill gap analysis, protocol validation, and real-time diagnostics. "We're no longer limited to what we can see," said Moran. "Now, we can measure, model, and improve with clarity, speed, and scale." A Strategic Vision for the Future of Surgery As part of its next phase of growth, Axis has announced its intent to align with a premier academic institution to co-develop a 36,000 sq. ft. smart surgical center—designed as a national hub for surgical innovation, clinical research, and medical education. This initiative is a logical and mission-aligned evolution of Axis's capabilities, combining physical infrastructure with proven technology and real-world surgical telemetry. By collaborating with the right university partner, Axis aims to accelerate translational research, bridge academic and industry priorities, and train future generations of surgeons within a connected, data-rich ecosystem. "Axis is committed to working with the ideal institutional partner—one that shares our belief that surgical excellence requires measurable feedback, collaborative design, and intelligent infrastructure," said Jill Goodwin, Chief Operating Officer of Axis. The company will continue developing the center in alignment with its founding principles—creating flexible, scalable environments that connect education, experimentation, and evidence—all in one location. Looking Ahead As Axis enters its second decade, it remains committed to being the platform for surgical progress—delivering training spaces, simulation technologies, and insights that help industry leaders bring better procedures, devices, and outcomes to life. About Axis Research & Technologies Axis operates a national network of advanced bioskills labs that support surgical training, cadaver-based research, and healthcare innovation. With hands-on environments, concierge-level support, and cutting-edge broadcasting and analytics capabilities, Axis serves as a trusted partner to medical device companies, health systems, and academic institutions. Learn more at About OMNIMED OMNIMED is the creator of SmartOR™, an AI-powered surgical telemetry platform that links classroom, simulation, and operating room data into a measurable, intelligent system. Used by educators, clinicians, and developers, SmartOR™ delivers actionable insights to improve training, device testing, and surgical performance. Learn more at View source version on Contacts Media Contact: Kim ShermanOpen Door Consultingkim@

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Yahoo

time23 minutes ago

  • Yahoo

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ('Jeune'), a wholly owned subsidiary of Krystal Biotech, Inc. ('Krystal') (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally reverse the biology of aging skin, announced today positive safety and efficacy results, including significant improvements in key skin aesthetic attributes such as wrinkles and elasticity, in PEARL-2, a randomized, double-blind, placebo-controlled Phase 1 study evaluating KB304, for the treatment of wrinkles of the décolleté. Meaningful aesthetic improvements were reported following KB304 treatment with clear and statistically significant advantages over placebo as evaluated by both the investigator and subjects using the Global Aesthetic Improvement Scale (GAIS). GAIS assesses the overall aesthetic change in appearance as a result of a treatment. Subjects also reported increased satisfaction with the appearance of wrinkles, as measured by the Subject Satisfaction Questionnaire (SSQ). The SSQ is a tool to gather subject-reported outcomes providing valuable insights on the impact of treatment beyond clinical observations. Topline Efficacy Results A total of 19 subjects were enrolled, 12 were randomized to KB304 and seven to placebo. One subject dropped out before completing KB304 treatments. The remaining 18 subjects were assessed for aesthetic improvement out to three months following KB304 injections in the décolleté. The study investigator and subjects reported a clinically meaningful improvement in wrinkles one, two, and three months after treatment, as assessed by GAIS among KB304-treated subjects. Investigator Reported: At Least One-Point Improvement for Subjects Receiving: Subject Reported: At Least One-Point Improvement for Subjects Receiving: KB304 Placebo KB304 Placebo At Three Months 100% 28.6% 72.7% 14.3% At Two Months 100% 28.6% 90.9% 14.3% At One Month 100% 14.3% 72.7% 14.3% As assessed by SSQ, 81.8% of subjects receiving KB304 reported improved satisfaction with their wrinkles' appearance three months after treatment, compared to 14.3% of subjects receiving placebo. Improvements in subjects receiving KB304 were also seen across multiple additional skin attributes, as assessed by GAIS, including elasticity, crepiness, hydration, and radiance, for which the investigator reported that 100% of subjects demonstrated an improvement of at least 1 point in each of these attributes at one, two, and three months following treatment. 'We are very excited to share today's data update. We are pleased that both the investigator and subjects reported high rates of improvements across a variety of skin attributes when treated with KB304. We believe that KB304 has the potential to revolutionize the treatment of wrinkles and skin quality by directly addressing the underlying biology of aging skin. KB304 is a truly unique product candidate, which we think will address a massive gap in the market two ways…being the first product candidate to directly address elastin and by doing so in the décolleté where there are no injectable products approved. Consumers are yearning for a solution that delivers natural looking results, and KB304 has the potential to restore the skin to a more youthful appearance,' said Marc Forth, Chief Executive Officer of Jeune. The KB304 safety profile was consistent with prior clinical experience in KB301. Adverse events were mild-to-moderate and mostly reported after the first dose but substantially tapered off with subsequent doses. No severe or drug-related serious adverse events were reported. 'We are extremely excited by the promising data from the Pearl-2 study,' said Suma Krishnan, President of Research & Development at Krystal Biotech. 'We believe KB304 has the potential to be a first-in-class treatment to deliver collagen and elastin directly to the skin. This study is the first randomized, double-blind, placebo-controlled trial to investigate the potential combinatorial benefits of COL3 and elastin supplementation when produced by the body's own skin cells. On the basis of the strong results and broad improvements across multiple skin aesthetic attributes, we will be progressing KB304 into Phase 2 development for the treatment of wrinkles in the décolleté, a priority aesthetic site for which no FDA-approved injectables exist. We plan to prioritize the development of KB304 and will be meeting with the FDA in the coming months to enable initiation of the Phase 2 study.' Jeune has recently completed development and validation of a décolleté-specific photonumeric scale ('JDWS'). Jeune intends to submit the JDWS to the FDA and align on the Phase 2 study protocol in the second half of 2025 with the goal of initiating the Phase 2 study in the first half of 2026. Conference Call and Webcast Jeune and Krystal will host a conference call and webcast today, Thursday, July 24, 2025, at 4:30pm ET, to discuss the results of the PEARL-2 study, the KB304 clinical development program, Jeune's pipeline product candidates, and the strategic vision for Jeune. Investors and the general public can access the live webcast at: For those unable to listen to the live webcast, a replay will be available on the Investor's section of the Krystal website at About KB304 KB304 is an investigational aesthetic therapy employing Krystal's novel replication-defective, non-integrating HSV-1-based vector to deliver two copies of the gene encoding COL3 transgene and one copy of the gene encoding elastin to increase their levels in skin and address signs of skin aging associated with damage to the skin's extracellular matrix. KB304 is formulated as a solution for direct intradermal injection to aesthetic priority areas. About the PEARL-2 Study PEARL-2 is a Phase 1 Study of KB304, a replication-defective, non-integrating vector expressing human type III collagen (COL3) and elastin for the treatment of moderate to severe wrinkles of the décolleté. Details of the Phase 1 study can be found at under NCT identifier NCT06724900. About Jeune Aesthetics, Inc. Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin. For more information, please visit About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company's first commercial product, is the first-ever redosable gene therapy, and the first genetic medicine approved by the FDA and EMA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit and follow @KrystalBiotech on LinkedIn and X (formerly Twitter). Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., or its wholly-owned subsidiary, Jeune Aesthetics, Inc., including statements about the clinical utility of KB304; KB304's ability to deliver collagen and elastin to restore the skin naturally to a more youthful appearance and potentially revolutionize the treatment of wrinkles and skin quality; KB304's potential to address a massive gap in the market; Krystal's and Jeune's plans to prioritize the development of KB304 and progress KB304 into a Phase 2 study for the treatment of wrinkles of the décolleté, including timing of meeting with the FDA and the goal of initiating the Phase 2 study in the first half of 2026; and other statements containing the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'predict,' 'project,' 'target,' 'potential,' 'likely,' 'will,' 'would,' 'could,' 'should,' 'continue,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: preliminary clinical data from a Phase 1 trial with a small sample size and limited follow-up may not predict results in later-stage studies; uncertainties associated with regulatory review of clinical trials, the availability or commercial potential of KB304, and such other important factors as are set forth under the caption 'Risk Factors' in Krystal's annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal's and Jeune's views as of the date of this press release. Krystal and Jeune anticipate that subsequent events and developments will cause their views to change. However, while Krystal and Jeune may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal's and Jeune's views as of any date subsequent to the date of this press release. CONTACT Investors and Media: Stéphane Paquette, PhD Krystal Biotech spaquette@ Nishant Saxena Jeune Aesthetics nsaxena@ in to access your portfolio

Neoadjuvant vs Adjuvant Immunotherapy in Colon Cancer
Neoadjuvant vs Adjuvant Immunotherapy in Colon Cancer

Medscape

timean hour ago

  • Medscape

Neoadjuvant vs Adjuvant Immunotherapy in Colon Cancer

The results of the phase III ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided about which treatment plan is the best. Adjuvant immunotherapy plus chemotherapy has yet to square off against neoadjuvant immunotherapy in a head-to-head trial. Even if that trial doesn't happen, post hoc analyses of ATOMIC and the neoadjuvant NICHE-2 studies may clarify whether a one-size-fits-all approach is appropriate and help determine which patients benefit more from one approach over the other, according to Christopher Lieu, MD, an investigator in the ATOMIC study. The ATOMIC study showed that adding adjuvant immunotherapy to standard-of-care chemotherapy following resection reduced the risk for disease recurrence or death by 50% compared with chemotherapy alone in the 355 patients with stage III colon cancer with mismatch repair deficiency (dMMR), who received adjuvant atezolizumab along with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy, providing those in the pro-adjuvant camp with important data. In addition, 3-year disease-free survival (DFS) was 86.4% with the combination compared with 76.6% with chemotherapy alone. The results of this trial were presented at the American Society of Clinical Oncology (ASCO) 2025. 'These data established this combination as a new standard treatment for patients with stage III colon cancer and deficient mismatch repair,' said study author Frank A. Sinicrope, MD, during a press conference at the meeting. 'We regard this as a highly impactful study that will change clinical practice, and it actually represents the first immunotherapy adjuvant study in colon cancer.' In NICHE-2, patients were given neoadjuvant ipilimumab or nivolumab followed by surgical resection. At 3 years, 100% of all 111 patients treated with ipilimumab and nivolumab prior to surgery were recurrence-free, according to a presentation at last year's annual meeting of the European Society for Medical Oncology (ESMO). The DFS beat the prespecified success threshold of 93%. Adding Immunotherapy The standard treatment for stage III colon cancer, regardless of dMMR status, is surgical resection followed by FOLFOX chemotherapy. However, about 15% of patients with stage III colon cancer have dMMR and display resistance to chemotherapy, providing a rationale for adding immunotherapies to standard treatment. 'These tumors are unable to repair their DNA and therefore accumulate mutations that trigger an immune response that is ineffective due to immune checkpoint proteins. Therefore, the use of immune checkpoint inhibitors is very attractive in this setting,' Sinicrope said during the press briefing. Sinicrope is professor of medicine and oncology, and coleader of the Gastrointestinal Cancer Program at Mayo Clinic in Rochester, Minnesota. Adjuvant Immunotherapy The ATOMIC trial is significant because it demonstrates improved DFS with the addition of immunotherapy to standard chemotherapy treatment, improving outcomes for patients with this type of locally advanced cancer over standard care. There are several rationales for adding immunotherapy following surgical resection. For example, staging relies on tumor appearance on CT scan, said Lieu, who is the codirector of Gastrointestinal Medical Oncology at the University of Colorado Cancer Center in Aurora, Colorado. There are patients with dMMR or microsatellite instability-high (MSI-H) colon cancer that appear to have stage I or II disease on their CT scan. 'In those patients, starting with immunotherapy first may not be the best idea because after a stage I or II colon cancer is resected, they don't require any further therapy because of the low risk of recurrence,' he said. 'If you think it is an early-stage cancer based of radiographic findings, you could cut out the cancer and then only offer chemotherapy and immunotherapy if it is unexpectedly stage III. I think that there's certainly rationale for that,' he continued. Other arguments for adjuvant immune checkpoint inhibitors, like atezolizumab, with chemotherapy include synergy between cytotoxic and immune mechanisms and systemic insurance against micrometastatic spread. It also avoids the potential for rare immune complications from upfront immunotherapy that could delay surgery. 'I don't think that [giving all patients neoadjuvant treatment] is the answer. If you think that they have stage I or stage II colon cancer at the beginning, then you might end up hurting them with upfront immunotherapy,' said Lieu. Neoadjuvant Immunotherapy The standard treatment for stage III colon cancer, regardless of dMMR status, is surgical resection followed by chemotherapy, FOLFOX and capecitabine and oxaliplatin (CAPOX) are two of the most common regimens. However, chemotherapy can be hard on patients, making neoadjuvant immunotherapy that can reduce or eliminate the need for post-surgical chemotherapy very attractive. The data from the NICHE-2 trial support the efficacy of neoadjuvant immunotherapy. 'The data strongly suggest that neoadjuvant immunotherapy is better than adjuvant immunotherapy and that chemotherapy for dMMR colorectal cancer has limited activity,' said Michael J. Overman, MD, Associate Vice President of Research for the MD Anderson Cancer Network in Houston, in an interview. 'Thus, I am a believer that neoadjuvant is the preferred approach for dMMR localized cancers.' Lieu said neoadjuvant immunotherapy might be more appropriate for more aggressive disease. 'What we discuss in our multidisciplinary clinic is that if these patients are diagnosed prior to surgery and particularly if they have aggressive features…those are some of the patients that I really would consider for neoadjuvant therapy,' he said. 'While it's high-risk disease, there could be some benefit to down-staging the patient, so that there isn't a positive margin. If there's pathologic complete response…and you don't have to give adjuvant chemotherapy, most people would consider that to be a win.' Overman noted that 'a big open area relates to whether the goal of neoadjuvant therapy should be operation or no operation. Likely both approaches can be done and that would be up to patient and physician.' However, 'with a nonoperative approach, we still have unknowns regarding disease assessment and surveillance for neoadjuvant therapy.' Patient-Specific Care In the absence of data from a head-to-head trial of the two approaches, a patient-specific approach may be the appropriate strategy, Lieu suggested. 'If I had a take home message, it's just that it's clear that these patients really require multidisciplinary discussion before an operation,' he said. Molecular testing has an important role to play as well, said Lieu. 'It speaks to the importance of doing biomarker testing for MMR, MSI, or both. Alarm bells should be ringing as soon as [either or both come] back positive; it should make everyone think for a second and make sure we have the right plan for the right patients.' Sinicrope reported several relationships, including with Eli Lilly, Guardant Health, Roche Holdings AG, Ventana Medical Systems, and Woven Health Collective. Lieu reported relationships with Amgen and Genentech.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store